{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:19:01Z","timestamp":1756311541280,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40290-019-00273-4","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T14:24:47Z","timestamp":1554474287000},"page":"121-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0231-0657","authenticated-orcid":false,"given":"Joanna","family":"Lem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Younus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal A.","family":"Aram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Moosavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Freivogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-9562","authenticated-orcid":false,"given":"Rachel E.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"273_CR1","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Module V\u2014risk management systems (Rev 2); 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129134.pdf . Accessed 13 March 2018."},{"key":"273_CR2","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Module XVI\u2014risk minimisation measures: selection of tools and effectiveness indicators (Rev 2); 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/02\/WC500162051.pdf . Accessed 13 March 2018."},{"key":"273_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14740338.2017.1335303","volume":"16","author":"A Rubino","year":"2017","unstructured":"Rubino A, Artime E. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006\u20132015. Expert Opin Drug Saf. 2017;16:877\u201384.","journal-title":"Expert Opin Drug Saf"},{"key":"273_CR4","unstructured":"European Medicines Agency. Mycamine: EPAR product information; 2011. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000734\/human_med_000911.jsp&mid=WC0b01ac058001d124 . Accessed 13 March 2018."},{"key":"273_CR5","unstructured":"US Food and Drug Administration. Vfend summary of product characteristics; 2008. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021266s023,021267s024,021630s013lbl.pdf . Accessed 13 March 2018."},{"key":"273_CR6","unstructured":"European Medicines Agency. VFEND summary of product characteristics; 2017. https:\/\/www.medicines.org.uk\/emc\/product\/7975\/smpc\/print . Accessed 13 March 2018."},{"key":"273_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/2040620713481796","volume":"4","author":"A Zabalza","year":"2013","unstructured":"Zabalza A, Gorosquieta A, Equiza EP, Olavarria E. Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review. Ther Adv Hematol. 2013;4:217\u201330.","journal-title":"Ther Adv Hematol"},{"key":"273_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bbmt.2008.12.491","volume":"15","author":"AR Patel","year":"2009","unstructured":"Patel AR, Turner ML, Baird K, Gea-Banacloche J, Mitchell S, Pavletic SZ, et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transpl. 2009;15:370\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"273_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D352H3F976","volume":"17","author":"RR Riahi","year":"2011","unstructured":"Riahi RR, Cohen PR. Voriconazole-associated phototoxicity. Dermatol Online J. 2011;17:15.","journal-title":"Dermatol Online J"},{"key":"273_CR10","first-page":"274","volume":"9","author":"S Vohringer","year":"2011","unstructured":"Vohringer S, Schrum J, Ott H, Hoger PH. Severe phototoxicity associated with long-term voriconazole treatment. J Dtsch Dermatol Ges. 2011;9:274\u20136.","journal-title":"J Dtsch Dermatol Ges"},{"key":"273_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jaad.2014.10.023","volume":"72","author":"J Sheu","year":"2015","unstructured":"Sheu J, Hawryluk EB, Guo D, London WB, Huang JT. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol. 2015;72:314\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"273_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00007890-201407151-00580","volume":"14","author":"M Mansh","year":"2014","unstructured":"Mansh M, Williams K, Binstock M, Hafeez F, Kim J, Glidden D, et al. Voriconazole exposure modifies risk for cutaneous squamous cell carcinoma, invasive aspergillosis and death in lung transplant recipients. Am J Transpl. 2014;14(Suppl 3):193.","journal-title":"Am J Transpl"},{"key":"273_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/tid.12367","volume":"17","author":"DJ Wojenski","year":"2015","unstructured":"Wojenski DJ, Bartoo GT, Merten JA, Dierkhising RA, Barajas MR, El-Azhary RA, et al. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis. 2015;17:250\u20138.","journal-title":"Transpl Infect Dis"},{"key":"273_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1586\/14787210.2015.1102053","volume":"13","author":"RK Goyal","year":"2015","unstructured":"Goyal RK. Voriconazole-associated phototoxic dermatoses and skin cancer. Expert Rev Anti Infect Ther. 2015;13:1537\u201346.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"273_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ajt.13431","volume":"16","author":"M Mansh","year":"2016","unstructured":"Mansh M, Binstock M, Williams K, Hafeez F, Kim J, Glidden D, et al. Voriconazole exposure and risk of cutaneous squamous cell carcinoma, aspergillus colonization, invasive aspergillosis and death in lung transplant recipients. Am J Transpl. 2016;16:262\u201370.","journal-title":"Am J Transpl"},{"key":"273_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/tid.12063","volume":"15","author":"JM McLaughlin","year":"2013","unstructured":"McLaughlin JM, Equils O, Somerville KT, Aram JA, Schlamm HT, Welch VL, et al. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart\/lung transplant patients. Transpl Infect Dis. 2013;15:329\u201343.","journal-title":"Transpl Infect Dis"},{"key":"273_CR17","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","volume":"209","author":"D Zonios","year":"2014","unstructured":"Zonios D, Yamazaki H, Murayama N, Natarajan V, Palmore T, Childs R, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209:1941\u20138.","journal-title":"J Infect Dis"},{"key":"273_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","volume":"40","author":"T Saito","year":"2012","unstructured":"Saito T, Fujiuchi S, Tao Y, Sasaki Y, Ogawa K, Suzuki K, et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection. 2012;40:661\u20137.","journal-title":"Infection"},{"key":"273_CR19","unstructured":"Practical approaches to risk minimisation for medicinal products: Report of CIOMS Working Group IX. Geneva: Council for International Organizations of Medical Sciences (CIOMS); 2014. https:\/\/cioms.ch\/shop\/product\/practical-approaches-to-risk-minimisation-for-medicinal-products-report-of-cioms-working-group-ix\/ . Accessed 13 March 2018."},{"key":"273_CR20","volume-title":"Survey methodology","author":"RM Groves","year":"2009","unstructured":"Groves RM, Fowler FJ Jr, Couper MP, Lepkowski JM, Singer E, Tourangeau R. Survey methodology. 2nd ed. New York: Wiley; 2009.","edition":"2"},{"key":"273_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40290-016-0161-7","volume":"30","author":"J Collins","year":"2016","unstructured":"Collins J, Bonneh-Barkay D. Considerations for successful risk-minimisation strategies in the EU. Pharm Med. 2016;30:257\u201361.","journal-title":"Pharm Med"},{"key":"273_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404\u201313.","journal-title":"Biometrika"},{"key":"273_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/pds.4434","volume":"27","author":"P Vora","year":"2018","unstructured":"Vora P, Artime E, Soriano-Gabarro M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies. Pharmacoepidemiol Drug Saf. 2018;27:695\u2013706.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"273_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40290-018-0248-4","volume":"32","author":"T Madison","year":"2018","unstructured":"Madison T, Huang K, Huot-Marchand P, Wilner KD, Mo J. Effectiveness of the crizotinib therapeutic management guide in communicating risks, and recommended actions to minimize risks, among physicians prescribing crizotinib in Europe. Pharm Med. 2018;32:343\u201352.","journal-title":"Pharm Med"},{"key":"273_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40290-017-0203-9","volume":"31","author":"KH Davis","year":"2017","unstructured":"Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2\u00a0mg\/ethinylestradiol 35 microg: a cross-sectional physician survey. Pharm Med. 2017;31:339\u201351.","journal-title":"Pharm Med"},{"key":"273_CR26","unstructured":"Madison T, Arias A, DiSantostefano R, Gilsenan A, Matus D, Primatesta P, et al. Evaluating the effectiveness of additional risk minimisation measures via surveys in Europe: challenges and recommendations; 2016. https:\/\/www.pharmacoepi.org\/pub\/?id=f46953df-de69-31e7-8f74-725bd7fa685f . Accessed 28 Jan 2019."},{"key":"273_CR27","unstructured":"EU GDPR Portal. EU General Data Protection Regulation (GDPR); 2018. https:\/\/www.eugdpr.org\/ . Accessed 13 March 2018."},{"key":"273_CR28","unstructured":"Center for Drug Evaluation and Research. Food and Drug Administration. Department of Health and Human Services. Risk evaluation and mitigation strategy assessments: social science methodologies to assess goals related to knowledge; 2012. https:\/\/www.pharmdevgroup.com\/wp-content\/uploads\/2014\/01\/REMS-FDA-Issue-Paper.pdf . Accessed 13 March 2018."},{"key":"273_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1503\/cmaj.080372","volume":"179","author":"KE Burns","year":"2008","unstructured":"Burns KE, Duffett M, Kho ME, Meade MO, Adhikari NK, Sinuff T, et al. A guide for the design and conduct of self-administered surveys of clinicians. CMAJ. 2008;179:245\u201352.","journal-title":"CMAJ"},{"key":"273_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/0163278713496425","volume":"36","author":"YI Cho","year":"2013","unstructured":"Cho YI, Johnson TP, Vangeest JB. Enhancing surveys of health care professionals: a meta-analysis of techniques to improve response. Eval Health Prof. 2013;36:382\u2013407.","journal-title":"Eval Health Prof"},{"key":"273_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1472-6963-9-160","volume":"9","author":"JV Cook","year":"2009","unstructured":"Cook JV, Dickinson HO, Eccles MP. Response rates in postal surveys of healthcare professionals between 1996 and 2005: an observational study. BMC Health Serv Res. 2009;9:160.","journal-title":"BMC Health Serv Res"},{"key":"273_CR32","first-page":"e225","volume":"58","author":"ER Wiebe","year":"2012","unstructured":"Wiebe ER, Kaczorowski J, MacKay J. Why are response rates in clinician surveys declining? Can Fam Physician. 2012;58:e225\u20138.","journal-title":"Can Fam Physician"},{"key":"273_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40290-017-0184-8","volume":"31","author":"E Agyemang","year":"2017","unstructured":"Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European Union: a review of the implementation and effectiveness of measures in the United Kingdom by one marketing authorisation holder. Pharm Med. 2017;31:101\u201312.","journal-title":"Pharm Med"},{"key":"273_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/pds.4392","volume":"27","author":"RE Sobel","year":"2018","unstructured":"Sobel RE, Bate A, Marshall J, Haynes K, Selvam N, Nair V, et al. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System\u2019s analytic tools. Pharmacoepidemiol Drug Saf. 2018;27:332\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"273_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-013-0126-7","volume":"37","author":"AK Banerjee","year":"2014","unstructured":"Banerjee AK, Zomerdijk IM, Wooder S, Ingate S, Mayall SJ. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation. Drug Saf. 2014;37:33\u201342.","journal-title":"Drug Saf"},{"key":"273_CR36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/pds.3596","volume":"23","author":"I Gridchyna","year":"2014","unstructured":"Gridchyna I, Cloutier AM, Nkeng L, Craig C, Frise S, Moride Y. Methodological gaps in the assessment of risk minimization interventions: a systematic review. Pharmacoepidemiol Drug Saf. 2014;23:572\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"273_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biomedicines6010006","volume":"6","author":"D Didona","year":"2018","unstructured":"Didona D, Paolino G, Bottoni U, Cantisani C. Non melanoma skin cancer pathogenesis overview. Biomedicines. 2018;6:6.","journal-title":"Biomedicines"},{"key":"273_CR38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40264-018-0662-2","volume":"41","author":"W Landsberg","year":"2018","unstructured":"Landsberg W, Al-Dakkak I, Coppin-Renz A, Geis U, Peters-Strickland T, van Heumen E, et al. Effectiveness evaluation of additional risk minimization measures for adolescent use of aripiprazole in the European Union: results from a Post-Authorization Safety Study. Drug Saf. 2018;41:797\u2013806.","journal-title":"Drug Saf"},{"key":"273_CR39","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","volume":"116","author":"JR Wingard","year":"2010","unstructured":"Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111\u20138.","journal-title":"Blood"},{"issue":"Suppl 7","key":"273_CR40","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.6004\/jnccn.2010.0135","volume":"8","author":"PE Johnson","year":"2010","unstructured":"Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, et al. NCCN oncology risk evaluation and mitigation strategies white paper: recommendations for stakeholders. J Natl Compr Cancer Netw. 2010;8(Suppl 7):S7\u201327.","journal-title":"J Natl Compr Cancer Netw"},{"key":"273_CR41","unstructured":"Alqvist-Radstad J, Andric A, Baldelli I, Coleman AM, Cupelli A, de Vries S, et al. SCOPE Work Package 6 Healthcare Professional Survey\u2014Medicines Safety Communications and their Effectiveness; 2016. http:\/\/www.scopejointaction.eu\/_assets\/files\/WP6-HCP-Survey-Report(1).pdf . Accessed 13 March 18."},{"key":"273_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","volume":"62","author":"EW Cowen","year":"2010","unstructured":"Cowen EW, Nguyen JC, Miller DD, McShane D, Arron ST, Prose NS, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62:31\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"273_CR43","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/pds.3450","volume":"22","author":"GJ Dal Pan","year":"2013","unstructured":"Dal Pan GJ. Commentary on \u201cThe effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey\u201d by Enger et al. Pharmacoepidemiol Drug Saf. 2013;22:716\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"273_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40290-017-0180-z","volume":"31","author":"V Frajzyngier","year":"2017","unstructured":"Frajzyngier V, Quintana A, Tucker H, Wible M, Hickman A, Baillon-Plot N, et al. An evaluation of the effectiveness of risk minimization measures for tigecycline in the European Union. Pharm Med. 2017;31:89\u201399.","journal-title":"Pharm Med"},{"key":"273_CR45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40264-014-0197-0","volume":"37","author":"MY Smith","year":"2014","unstructured":"Smith MY, Morrato E. Advancing the field of pharmaceutical risk minimization through application of implementation science best practices. Drug Saf. 2014;37:569\u201380.","journal-title":"Drug Saf"},{"key":"273_CR46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/TCRM.S78202","volume":"11","author":"EH Morrato","year":"2015","unstructured":"Morrato EH, Smith MY. Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved. Ther Clin Risk Manag. 2015;11:339\u201348.","journal-title":"Ther Clin Risk Manag"},{"key":"273_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12874-015-0016-z","volume":"15","author":"CT Cunningham","year":"2015","unstructured":"Cunningham CT, Quan H, Hemmelgarn B, Noseworthy T, Beck CA, Dixon E, et al. Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol. 2015;15:32.","journal-title":"BMC Med Res Methodol"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-019-00273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40290-019-00273-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-019-00273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T10:11:31Z","timestamp":1663236691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40290-019-00273-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1007\/s40290-019-00273-4","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"type":"print","value":"1178-2595"},{"type":"electronic","value":"1179-1993"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Pfizer. The open access fee was funded by Pfizer. An honorarium payment for completing a survey was offered to HCPs in Spain (pursuant to local laws and country regulations).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Joanna Lem, Muhammad Younus, Shahrzad Moosavi, Jalal A. Aram, and Rachel E. Sobel are employees and shareholders of Pfizer, the manufacturer of voriconazole. Klaus Freivogel is an employee of United BioSource, a contract research organization that has received research grants from Pfizer to conduct the research. Anne Lewis is a former contractor employee of United BioSource and a current Principal of Clermont Consulting Group, LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The final prescriber survey protocol and survey questionnaire were submitted to local regulatory authorities such as ethics committees, where required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}